Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VKTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsViking Therapeutics raises ~$547.8M via equity and convertible notes to fund VK2735 and VK3019
Filed September 28, 2026 · Period ending September 23, 2026 · ~1 min read
Key Changes
-
high
Sold 7,857,143 shares at $35.00 per share; underwriters' option for 1,178,571 additional shares was exercised in full, netting ~$297.0M.
Item 1.01 verify on EDGAR → -
high
Issued $225M of 2.00% Convertible Senior Notes due 2032; underwriters' option for up to $33.75M additional notes was exercised in full, netting ~$250.8M.
Item 1.01 verify on EDGAR → -
medium
Notes convert at ~$50.75 per share, a premium to the $35.00 equity offering price; conversion rate subject to adjustment and Make-Whole Fundamental Change.
Item 1.01 verify on EDGAR → -
medium
Proceeds earmarked for VK2735 and VK3019 clinical development, plus general R&D, working capital, and corporate purposes.
Item 1.01 verify on EDGAR → -
low
Company may redeem notes starting October 22, 2029 if stock exceeds 130% of conversion price; cleanup redemption available below 15% outstanding.
Item 1.01 verify on EDGAR →
Summary
Viking Therapeutics raised approximately $547.8 million in net proceeds through concurrent equity and convertible note offerings. The equity offering sold 7,857,143 shares at $35.00 per share, and the underwriters' option for an additional 1,178,571 shares was exercised in full, generating about $297.0 million.
The debt offering issued $225 million of 2.00% Convertible Senior Notes due 2032, with the underwriters' option for up to $33.75 million more also fully exercised, netting roughly $250.8 million. The notes convert at an initial price of approximately $50.75 per share, a premium to the equity offering price.
Proceeds are intended primarily for the continued clinical development and advancement of the VK2735 and VK3019 programs, with the remainder for general research and development, working capital, and corporate purposes. The company may redeem the notes starting October 22, 2029 if the stock price exceeds 130% of the conversion price for the required period. For retail holders, this financing strengthens the balance sheet to advance key pipeline candidates but introduces potential dilution from both the new shares and future note conversions. The conversion premium suggests confidence in the stock's upside, while the redemption provision gives the company flexibility to retire the debt if the share price performs well.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Viking Therapeutics raised ~$547.8M via concurrent equity and convertible note offerings to fund VK2735 and VK3019 development.
Added in current filing · verify on EDGAR →
The Company currently intends to use the net proceeds from the Equity Offering and the Debt Offering for the continued clinical development, advancement and commercialization of its VK2735 program, the continued clinical development and advancement of its VK3019 program and for other general research and development, working capital and general corporate purposes.
Proceeds are earmarked primarily for the VK2735 and VK3019 clinical programs, with the remainder for general R&D, working capital, and corporate purposes. This signals continued investment in the company's pipeline.
Event · Item 2.03 — Creation of a Direct Financial Obligation
Viking Therapeutics discloses a debt offering, incorporating Item 1.01 details by reference.
Added in current filing · verify on EDGAR →
The information set forth under the heading “Debt Offering” in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
The company created a direct financial obligation through a debt offering. The specific terms are incorporated by reference from Item 1.01, which is not included in this section of the filing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 29, 2026 · How we verify